Logo image of EQRX

EQRX INC (EQRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EQRX - US26886C1071 - Common Stock

2.34 USD
-0.05 (-2.09%)
Last: 11/8/2023, 8:00:02 PM
2.39 USD
+0.05 (+2.14%)
After Hours: 11/8/2023, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EQRX. EQRX was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for EQRX as it has an excellent financial health rating, but there are worries on the profitability. EQRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year EQRX has reported negative net income.
  • EQRX had a negative operating cash flow in the past year.
EQRX Yearly Net Income VS EBIT VS OCF VS FCFEQRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -20.04%, EQRX belongs to the top of the industry, outperforming 81.92% of the companies in the same industry.
  • The Return On Equity of EQRX (-21.05%) is better than 85.07% of its industry peers.
Industry RankSector Rank
ROA -20.04%
ROE -21.05%
ROIC N/A
ROA(3y)-22.45%
ROA(5y)N/A
ROE(3y)-23.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EQRX Yearly ROA, ROE, ROICEQRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 50 -50 100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EQRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQRX Yearly Profit, Operating, Gross MarginsEQRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, EQRX has more shares outstanding
  • EQRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EQRX Yearly Shares OutstandingEQRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 100M 200M 300M 400M
EQRX Yearly Total Debt VS Total AssetsEQRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 11.47 indicates that EQRX is not in any danger for bankruptcy at the moment.
  • EQRX has a better Altman-Z score (11.47) than 91.54% of its industry peers.
  • EQRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.47
ROIC/WACCN/A
WACCN/A
EQRX Yearly LT Debt VS Equity VS FCFEQRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 500M 1B 1.5B

2.3 Liquidity

  • EQRX has a Current Ratio of 22.60. This indicates that EQRX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 22.60, EQRX belongs to the best of the industry, outperforming 96.02% of the companies in the same industry.
  • A Quick Ratio of 22.60 indicates that EQRX has no problem at all paying its short term obligations.
  • EQRX's Quick ratio of 22.60 is amongst the best of the industry. EQRX outperforms 96.02% of its industry peers.
Industry RankSector Rank
Current Ratio 22.6
Quick Ratio 22.6
EQRX Yearly Current Assets VS Current LiabilitesEQRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for EQRX have decreased strongly by -62.64% in the last year.
EPS 1Y (TTM)-62.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, EQRX will show a decrease in Earnings Per Share. The EPS will decrease by -9.08% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-92.67%
EPS Next 2Y-37.78%
EPS Next 3Y-19.35%
EPS Next 5Y-9.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EQRX Yearly Revenue VS EstimatesEQRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
EQRX Yearly EPS VS EstimatesEQRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • EQRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EQRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQRX Price Earnings VS Forward Price EarningsEQRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQRX Per share dataEQRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • EQRX's earnings are expected to decrease with -19.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-37.78%
EPS Next 3Y-19.35%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for EQRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EQRX INC

NASDAQ:EQRX (11/8/2023, 8:00:02 PM)

After market: 2.39 +0.05 (+2.14%)

2.34

-0.05 (-2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)N/A
Inst Owners3.06%
Inst Owner Change0%
Ins Owners0.52%
Ins Owner Change0%
Market Cap1.26B
Revenue(TTM)N/A
Net Income(TTM)-262.78M
Analysts42.86
Price Target2.14 (-8.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.13%
Min EPS beat(2)-15.79%
Max EPS beat(2)-8.46%
EPS beat(4)2
Avg EPS beat(4)16.22%
Min EPS beat(4)-15.79%
Max EPS beat(4)75.91%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-17.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS2.32
TBVpS2.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.04%
ROE -21.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.45%
ROA(5y)N/A
ROE(3y)-23.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 203.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.6
Quick Ratio 22.6
Altman-Z 11.47
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)346.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y-92.67%
EPS Next 2Y-37.78%
EPS Next 3Y-19.35%
EPS Next 5Y-9.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.34%
EBIT Next 3Y2.85%
EBIT Next 5Y0.08%
FCF growth 1Y-57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.82%
OCF growth 3YN/A
OCF growth 5YN/A

EQRX INC / EQRX FAQ

What is the fundamental rating for EQRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to EQRX.


Can you provide the valuation status for EQRX INC?

ChartMill assigns a valuation rating of 0 / 10 to EQRX INC (EQRX). This can be considered as Overvalued.


What is the profitability of EQRX stock?

EQRX INC (EQRX) has a profitability rating of 2 / 10.


Can you provide the financial health for EQRX stock?

The financial health rating of EQRX INC (EQRX) is 8 / 10.